R&D Sponsored Obesity and the endoscopy space: Innovative, minimally invas... According to the World Health Organization (WHO), in 2022, 2.5 billion adults aged 18 years and older were overweight, including over 890 million adults who were living with
Market Access Boehringer US head covers GLP-1s, PBMs, Trump at Reuters USA Brian Hilberdink, Boehringer Ingelheim's new Head of US Human Pharma, fielded questions on a variety of hot topics from the Reuters Pharma USA stage.
Market Access UK weight loss market: M&A opportunities Recent advancements in weight-loss interventions are transforming the healthcare landscape and presenting new M&A opportunities
News Novo Nordisk follows Lilly into DTC obesity drug market Novo Nordisk has launched direct-to-consumer sales of its obesity drug Wegovy for uninsured or under-insured people at $499 per month.
News Small study finds GLP-1 drug can curb excess alcohol use Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder.
Digital Looking beyond the scale: Why measures of physical activity ... GLP-1 receptor agonists like Ozempic and Wegovy are dramatically changing how healthcare professionals approach the treatment of obesity in patients.
News uniQure falls on long-term Huntington's gene therapy data uniQure's latest data drop for its gene therapy for Huntington's disease, under review in the US and UK, has spooked investors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.